Nasdaq:US$18.41 (+0.16) | HKEX:HK$30.35 (+1.05) | AIM:£3.03 (+0.07)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 5 Nov 2009

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

1 items
a091105